a brief review on captisol

© 2020 JETIR November 2020, Volume 7, Issue 11 www.jetir.org (ISSN-2349-5162)

JETIR2011280 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 1036

A BRIEF REVIEW ON CAPTISOL

1Pawar Pooja. S, 2Dr. Kalkotwar Ramesh. S, 3Mahanubhav Pooja. T

1. Research Scholar, SND College of Pharmacy Babulgaon, Yeola, Dist-Nashik (423401)

Maharashtra

2. Research Guide, SND College of Pharmacy Babulgaon, Yeola, Dist-Nashik (423401)

Maharashtra

3. Research Scholar, SND College of Pharmacy Babulgaon, Yeola, Dist-Nashik (423401)

Maharashtra

I. ABSTRACT

A systematic study led to SBE-β-CD (Captisol), a polyanionic variably substituted sulfobutyl ether of β-CD, SBE-β-CD have

undergone extensive safety studies and are currently used in six products approved by the Food and Drug Administration (four

for Captisol and two for HP-β-CD). In many medical and preclinical trials, they are also in use. This article will concentrate

on recent SBE-β-CD patents and the issues that led to product development, their safety, applications, and in particular their

ability to improve drug delivery.

SBE-β-CD interacts very well with neutral drugs to facilitate solubility and chemical stability and interacts particularly well

with cationic drugs due to its polyanionic natureInclusion combinations of SBE-β-CD and various drugs have been used to

dissociate rapidly after injection of parenteral drugs, to have no tissue-irritating impact after intramuscular dosing and to result

in the superior oral bioavailability of badly water-soluble medications.The bioavailability enhancement and the solubility of

some SBE-β-CD drugs were studied..

Keywords: Captisol, sulfobutyl,

II. INTRODUCTION

Captisol is protected by patents, specially adapted cyclodextrin with a reasonable chemical structure aimed to improving

protection and optimize communication to boost solubility, stability and bioavailability or to reduce volatility, discomfort,

odor and taste. Captisol is a polyanionic beta-cyclodextrin synthetic version with a sodium sulfonate salt separated by a group

of butyl ether spacers or sulfobutylther from the lipophilic region. (SBE).[1] Captisol is not an independent chemical organism,

Nevertheless, it consists of a multitude of polymeric materials with varying extents of replacement and positional / regional

isomers determined and regulated by a proprietary manufacturing process continuously practiced and enhanced for impurity

control.Captisol's choice and its favorable safety profile and properties of drug solubilization are based on extensive

evaluations of the controlled formulations mono, tetra and hepta-replaced. Many hundred pre-clinical and clinical studies have

been conducted suggesting that Captisol is secure when administered IV or orally and do not show beta-cyclodextrin-related

nephrotoxicity. Captisol offers higher contact properties and higher water solubility in enhanced of 100 grams/100 ml

compared to beta-cyclodextrin – a 50-fold boost[2]

III. HISTORY

In 1990, Captisol has been developed for use in the production and manufacture of drugs by scientists at the University of

Kansas Higuchi Biosciences Center .The technology of Captisol is used to address the limitations of drugs currently on the

market. Captisol-enabled, FDA-approved drugs are sold by Pfizer, Bristol-Myers Squibb, and Baxter International. Captisol

also has Permit and Distribution Agreements (LSAs) with a number of Captisol-enabled pharmaceutical companies

worldwide. Parenteral, dental, ophthalmic, nasal, topical, respiratory, and inhalation routes of administration studied.

Captisol's regulatory acceptance is backed by comprehensive safety studies showing its excellent systemic mechanism of

action.

In 1999, the FDA issued a Form V Drug Master File (DMF). This regulatory package of safety data, which includes more than

70 volumes, promotes the use of Captisol in parenteral products and promotes other distribution routes. The data package was

reviewed by several FDA divisions and ex-US regulatory agencies and authorized the use of Captisol in clinical tests.

http://www.jetir.org/



IV. SALIENT FEATURES

The production of drug is a lengthy mechanism through development and marketing by exploration and evaluation. Captisol

offers an elegant and efficient Solution of the obstacles to solubility and reliability in each development phase.Combinatorial

chemistry, high-performance screening (HTS) and molecular genetics have resulted in an increase in the number of insoluble

and unstable molecules, peptides and proteins being tested for therapeutic activity

FORMULATION APPLICATION

Improved Bioavalibility

Tabuteau et al. The composition of drug with SBE-beta-CD used to enhance the absorbtion or pharmacokinetics

of the drug for the treatment of conditions such as pain[3]

Zongyin Q etal. Prepared formulation containing Orlistat into the inclusion compound, and sulfobutylether-beta-

cyclodextrin which can increase the bioavalibility of drug and enhance the stability of a medicine.[4]

Jiang Yina etal. The use of SBE-beta-CD improve the solubility of GCV and the stability and the permeable cornea

absorption of GCV, so that the bioavailability of GCV and the safety of a preparation are improved.[5]

Improved Solubility

Captisol is a cyclic sugar that has a large hydrophobic cavity and an outer hydrophilic. Makes water-insoluble API formulation

in all types of medication, including oral, injectable, ophthalmic, nasal, topical, and inhalation drugs. Better solubility than

techniques of solubilization using nanoparticles and solvent methods.




Table No.1 Captisol Patent For Improve bioavalability

Horvath etal. Studied preparations of receptor tyrosine kinase blockers (TKI) pazopanib and their formulation processes and

the use of reported medications in the current the active agent is sent to the target site. He evaluated that th captisol used in

designing and implementing shoes increases peaceopanib's bioavailability and stabilization.[7]

Crawley et al.

Developed transdermal non-patch pergolide medication that is beneficial for the management of disease in an equine, the

innovation also offers techniques for the diagnosis of an equine disease by administering an invention medication to an equine;

the function of captisol in this formulation was to increase the solubility of the pergolide.[8]

Choon. K et al

Constructed carvedilol medication and procedure of using this formulation in the treatment of hypertension and congestive

heart failure, captisol was used in this formulation to improve the drug's solubility and safety, the drug's solubility increased

by 10 folds.[9]

Rowe. V et al

Manufactured compositions and processes to decreses renal damage caused by nephrotoxic products. The discovery produces

compositions containing an anionically substituted oligosaccharide, a nephrotoxic drug and. A pharmaceutically appropriate

carrier where captisol's function in this formulation is to improve methotrexate solubility in aqueous acid solution.[10]

Patent Number Drug Purpose Patentee Year Reference

US2018/021438

0 A1

Rizatriptane,

Meloxicam

Purpose of the SBE-

beta-CD in these

study was to improve

Bioavailability of

drug

Herriot

Tabuteau

2018 [3]

CN106943605A

Antineoplastic SBE-beta-CD

used in these study

for formation of

inclusion complex

with orlistat

Zongyin

Qiu

2017 [4]

CN104606682A

Ganciclovir

Improves the

Bioavilablity and

stability of

ganciclovir

Jiang

Yina

2015 [5]




Shang Jingchuan etal.

SBE-P-CD is primarily used for increasing product solubility and stability, improving bioavailability, adjusted release,

preventing the escape of volatile components, improving bad odor, reducing discomfort, reducing side effects.[11]

Table No.2 Captisol Patent For Improve Solubility

Improved Stability

The API protection from oxidative and hydrolytic degradation Interaction with Captisol Protects from damage from conditions

such as heat and light.

Antle etal

Captisol has discovered formulations composed of fractionated alkylated cyclodextrin compounds with a single degree of

substitution and processes for their preparation and use.[12]

Patent Number Drug Purpose Patentee Date Reference

US 9 , 895 , 369 B2 Pazopanib Increases solubility

and Stability of

pazopanib

Judit Horvath,

Irina Astafieva,

Signe Erickson,

Kathleen Farinas

2018 [7]

US 9 , 987 , 267 B2 Pergolide Increase in solubility

of pergolide

Sara crawley,

Amy marr ,

Jane Owens ,

2018 [8]

CN105031663B Luteolin

Improved solubility of

luteolin by captisol

Shang Jingchuan

2015 [11]

WO2007/062403 A2 Methotrexate Shows increase

solubility results

with methotrexate

in aqueous acidic

solution.

Vernon d. Rowe

2007 [10]

WO03/028718 A Carvedilol Shows increased in

solubility by 10 folds,

and improvement in

stability of drug

Choon, k 2003 [9]




Pipkin et al.

Formulated fluid solution containing SAE CD and corticosteroid inhalable unit dosage. The composition is modified by

nebulization with any known nebulizer for injection to a subject. It is possible to include the synthesis in a kit. The product is

given as a condensed or aqueous medium. In an improved nebulization system, the formulation is used to administer inhalation

corticosteroids.[13]

Antle et al. We demonstrate that significant removal of both a phosphate and a drug-degrading impurity from a formulation of SAE-CD

produces a composition that can be easily combined with an active agent to provide a highly stable formula.

Sabina et al.

Studies have shown that the use of SBE-CD in the formulation of antibiotic glycopeptides has significantly increased

composition stability.[14]

Shang Jingchuan etal.

By incorporating the SBE-beta-CD as an auxiliary material, resveratrol is strengthened in water solubility and stability.[15]

Tong Keqin etal.

The formulation has the benefits of high-cabazitaxel solubility, high consistency, long, balanced redissolution time and

medical convenience.[16]

Reddy K et al.

The formulation containing neuroactive steroid and SBE-beta-CD used in this study was designed to improve allopregnanolone

stability.[17]

Table No.3 Captisol Patent For Improve Stability

Patent Number Drug Purpose Patentee Year Refere

nce

CN108066774A

Cabazitaxel

Improve the stability

of cabazitaxel

Tong Keqin

2018 [16]

WO2017194385A1

Vancomycine Improves the stability

of glycopeptides

antibiotics

Sabina K

2016 [14]

CN105903033A

Resveratrol Improved stability of

resveratrol

Shang Jingchuan

2016 [15]

WO2013/112605 A2 Allopregnanolone To improve the

stability of drug

Reddy 2013 [17]

US 7,635,773 B2 Aripiprazole Improves the stability

of API

Vincent Antle,

Olathe, KS

2009

US2007/0020196 A1 Budesonide Enhances the

chemical stability of

corticosteroid.

James D. Pipkin,

Rupert O. Zimmerer,

Diane O. Thompson,

Gerold L. Mosher,

2007 [13]




V. PARENTRAL

Captisol is an excipient used to improve solubility in certain medication injectable products, Captisol is a modified

cyclodextrin that can form combinations of ionics and incorporation with many kinds of drugs.

Complexation can increase the solubility greatly, and often times, the drug's physical chemical stability. Complexation was

also used to improve dissolution and bioavailability, to reduce volatility, to allow liquids to be integrated into solid

formulations,and Minimize severe side effects such as taste and discomfort from drug contact with skin, e.g. injection site

extravasation and GI discomfort.

Thompson et al.

Prepared injectable formulation of a hypnotic sedative drug, such as anesthetic drug propofol, which is pharmaceutically stable

and also shows a reduced incidence of pain upon injection.

A Sulfoalkyl ether cyclodextrin solubilizing and complexing excipient such as captisol cyclodextrin (sulfobutyl ether B-

cyclodextrin) is used in the formulation of the present invention to create a true aqueous solution rather than a suspension He

also studied the formulations mitigate the allergic reaction and the problems of bacterial contamination usually associated with

parenteral formulations of propofol. The present formulation can also minimize injection pain compared to the known propofol

formulations of the emulsion type.[18]

Fan et al Invented parenteral formulations screening methods involving Small quantities of drugs and fast tests. The procedure

involves steps to classify one or more solutions for reconstitution and to apply the solutions to combinations of lyophilized

products, excipients and diluents.[19]

Zhang et al. Prepared an parentral ganaxolone preparation consisting of ganaxolone, sulfobutyl ether-B cyclodextrine and ganaxolone

water and sulfobutyl ether-B-cyclodextrine formed an inclusion complex, the function of captisol used in this formulation is

to shape a complex inclusion.[20]

Robert, G et al. An intravenous pharmaceutical composition or kit comprising 4-(pyrimidin-2-ylmethyl)-7-(4-

(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[i][1,4]oxazepin-5(2H)-one (Compound I) and a beta-cyclodextrin derivative.

Captisol enhances the solubility of eleclazine.[21]

Table No.1 Captisol Patent For Parentral Formulation

VI. CAPTISOL® AN EFFICIENT CARRIER AND SOLUBILIZING AGENT IN OIL

Essential oils (EOs) and their individual segments have a few organic properties and are utilized in beauty care

products, food and pharmaceutical businesses. Be that as it may, their application despite everything presents a

test owing for the most part to their instability and their poor watery dissolvability and security. The point of this

examination was to assess, just because, the capacity of Captisol® (sulfobutylether‐β‐cyclodextrin, SBE‐β‐CD)

Patent Number Drug Purpose Patentee Year Reference

WO 2017/007805 Al Eleclazine Captisol enhances the

solubility of drug

Strickley Robert G 2017 [21]

US2016/0228454 A1 Ganaxolone The purpose of captisol

used in these formulation

is for formation of

inclusion complex

Mingbao Zhang,

Raymond C. Glowaky

2016 [20]

US2015/0316568 A1 Fleroxacin For improve the

solubility of drug

captisol was used in this

parentral formulation.

Mingjin Fan,

Ujjwal Joshi,

Jonathan Cam Ly,

Akash Jain

2015 [19]

US 7,034,013 B2 Propofol Captisol used in the

formulation for the

purpose to stabilize the

parentral formulation

Diane O. Thompson,

Gerold L. Mosher

2006 [18]




and Captisol‐G® (sulfobutylether‐γ‐cyclodextrin, SBE‐γ‐CD) to epitomize the fundamental unstable segments of

six basic oils (EOs), to upgrade the fluid dissolvability of these EOs and to produce controlled delivery

frameworks. The exhibition of these CDs was contrasted with hydroxypropyl‐β‐cyclodextrin (HP‐β‐CD) and γ‐

cyclodextrin (γ‐CD), separately. Arrangement constants (Kf) of the 40 consideration buildings were controlled

by Static Headspace‐ Gas Chromatography (SH‐GC). At that point, Total Organic Carbon (TOC) was utilized to

investigate and evaluate the productivity of Captisol® and HP‐β‐CD to improve the dissolvability of the six EOs.

At last, different headspace extraction (MHE) was applied to perform discharge examines. Kf values underlined

the best restricting capability of Captisol® towards all visitors. HP‐β‐CD enormously expanded the clear solvency

of EOs. The solubilizing potential was contrarily proportionate to the EOs inborn dissolvability (SEO). Results

demonstrated that Captisol® can effectively epitomize EOs, increment their obvious fluid solvency and reduction

their delivery energy. Along these lines, Captisol® could be considered as a promising transporter to develop the

use of EOs and their segments.[22]

Essential oils (EOs) and their individual segments are commonly perceived as enhancing and scent operators in

beauty care products and food industries.[23] They can likewise be utilized in pharmaceutical and clinical

applications for their cancer prevention agent, antimicrobial and anti‐inflammatory exercises or to kill unfortunate

taste of severe drugs.[24]EOs and their segments are very much acknowledged by purchasers because of their

characteristic beginning and nutraceutical potential. Nonetheless, a significant issue is the low dissolvability and

soundness just as the high unpredictability of EOs and their segments that limit their application in the diverse

fields.[25] Moreover, they do dissipate recommending a requirement for embodiment. A technique for upgrading

EOs dissolvability is their sub-atomic epitome by cyclodextrins (CDs).[26] CDs are cyclic oligosaccharides gotten

from enzymatic corruption of starch. They have a shortened shape with a hydrophilic surface and a hydrophobic

cavity that permits them to epitomize visitors and structure consideration edifices in arrangement or in strong

state.[27] The most widely recognized local CDs are α‐, β‐ and γ‐CDs and are comprised of six, seven and eight

glucosyl units, individually. Fusing EOs as consideration edifices in corrective, food or pharmaceutical details

present a few favorable circumstances. Discs may improve the dissolvability of EOs and their parts in this manner

higher fixations could be utilized.[28] produce simple quantifiable measurements structures, encourage their

scattering and shield them from interactionswith other excipients.[29] CDs could likewise hold and permit a

controlled delivery for EO’s[30] offer them warm, oxidative, light and compound stability [31]and increment

their oral bioavailability.[32]as far as we could possibly know no past examination endeavored to explore the

incorporation buildings of Captisol® (sulfobutylether‐β‐cyclodextrin, SBE‐β‐CD) and Captisol‐G®

(sulfobutylether‐γ‐cyclodextrin, SBE‐γ‐CD) with Eos and their segments while, contrasted with local CDs, these

CDs display more noteworthy water solvency and a more attractive security profile.

VII. APPLICATIONS IN PHARMACEUTICAL FORMULATION OR TECHNOLOGY

Cyclodextrins are nonhygroscopic, cyclic oligosaccharides got from starch Sulfobutylether bcyclodextrin is a

shapeless, anionic subbed b-cyclodextrin Derivative other subbed cyclodextrin subsidiaries are additionally

accessible Sulfobutylether b-cyclodextrin can frame noncovalent buildings with numerous sorts of mixes

including little natural particles, peptides[33]and proteins.[34] It can likewise upgrade their solubility[35] and

stability[36] in water. The principal use of sulfobutylether bcyclodextrin was in injectable preparations;[37] it can

likewise be utilized in oral solid[38] and fluid measurement structures, and ophthalmic,[39] inward breath, and

intranasal formulations.[40] Sulfobutylether bcyclodextrin can work as an osmotic specialist as well as a

solubilizer for controlled-discharge delivery,[41] and has antimicrobial additive properties when present at

adequate fixations. The measure of sulfobutylether b-cyclodextrin that might be utilized is subject to the reason

for consideration in the definition, the course of organization, and the capacity of the cyclodextrin to complex

with the medication being conveyed. The base sum required for solubilization is, when all is said in done, a

cyclodextrin/medicate molar proportion of roughly 1–5 (the specific proportion being tentatively decided from

complexation information). The greatest use in a definition might be restricted by physicochemical limitations,

for example, thickness (for example syringeable focuses might be considered up to half w/v), constitution, or the

complete weight and size of strong dose structures (for example not exactly a gram in an individual tablet).[42]

It might likewise be restricted by pharmacokinetic/pharmacodynamic (PK/PD) contemplations. As weakening of




a cyclodextrin definition prompts an expansion in the measure of uncomplexed sedate, plans that are not

weakened upon organization, for example, ophthalmic details, are touchy to cyclodextrin concentration.[43] In

plans, for example, these, cyclodextrin focuses more noteworthy than the base required for solubilization can

lessen the accessibility of uncomplexed medicate and in this manner influence PK/PD desires by creating impacts,

for example, more slow beginning, lower Cmax, and bioavailability.[44]

VIII. CURRENT PROSPECTIVE ON CAPTISOL

When the Food and Drug Administration issued an emergency-use authorization for the investigational pharmaceutical

remdesivir to treat COVID-19 on May 1, in part it was due to pioneering work performed by pharmaceutical chemists at the

University of Kansas School of Pharmacy in 1990. Today, KU graduates still hold important jobs at the firms producing and

distributing the potentially life-saving therapy to people around the world during the coronavirus pandemic.[45] Remdesivir's

formulation includes the solubilizer Captisol, developed at KU, which allows remdesivir be administered to the patient.

Captisol was invented and patented by Valentino Stella, University Distinguished Professor Emeritus, and Roger Rajewski,

research professor in the Department of Pharmaceutical Chemistry "We use Captisol as an excipient to enhance the aqueous

solubility and chemical stability of remdesivir," said KU alumnus Reza Oliyai, senior vice president for pharmaceutical and

biological operations at Gilead, the manufacturer of remdesivir. "All of us at Gilead are committed to doing everything we can

to help address the global COVID-19 pandemic.[46] The work of Professor Valentino Stella and also Dr. Roger Rajewski.at

the University of Kansas has played a key role in the development of the remdesivir product that is being evaluated now for

the treatment of COVID-19 infection." As co-inventor Stella himself recently detailed in a history of Captisol, at the time of

its invention there was a need for a new solubilizer for cancer and other therapies to replace surfactant-based solubilizers that

were leading to dire complications for patients. "A lot of drugs don't dissolve in water, or they're chemically unstable because

of their physical and chemical properties," Stella said. "So, if you want to give a drug by intravenous injection, it's got to be

in solution. You cannot inject particles into your vein that get trapped by the lung and you end up with a lung embolism. Also,

if you take the drug orally with a tablet, they've got to dissolve in the gastrointestinal tract. If a drug is extremely insoluble,

it's not absorbed and doesn't dissolve while it's going down the GI tract. So, there's a need for solubilizers to modify the

properties of a drug."

Stella and Rajewski landed on the idea for the uniquely modified cyclodextrin, which came to be called Captisol, over beers

one night. They were ironing out the path of Rajewski's doctoral research to develop a less toxic solubilizer for cancer drugs.

At the time, Rajewski was Stella's graduate student. Rajewski had the idea to modify the position of the cyclodextrin molecule's

charge so it could solubilize drugs without also dangerously interacting with cholesterol in the body. "We thought we could

get the safety and have the binding back, and that was what ended up working," Stella said. Before Rajewski publicly defended

his doctoral thesis on the new solubilizer, the pair filed a patent on their invention that also would pay royalties to KU. A

startup firm called CyDex was spun out of the research to produce and market Captisol. Eventually, that firm worked with

Pfizer but today Captisol is manufactured and marketed by the firm Ligand. It's in the formulation of more than a dozen

therapies on the market, including Kyprolis, Vfend IV, Noxafil Injection, Zulresso, Evomela and Nexterone. But it's the

solubilizer's inclusion in remdesivir that's most notable during a global pandemic that's cost so many lives and decimated

economies around the globe. "It's gratifying to know the results of research I conducted in the Department of Pharmaceutical

Chemistry here at KU are playing a role in the formulation of remdesivir for COVID-19 patients," Rajewski said. "While I

was fortunate to be involved in the invention of Captisol more than 30 years ago, the development of Captisol for human use

was the culmination of efforts by many individuals, both at CyDex and then Ligand. Likewise, the ingenuity of scientists such

as those at Gilead leading to drugs like remdesivir is humbling.[47] The KU community should be proud to be part of the team

that makes such treatments possible." Like Rajewski and Oliyai, many key players in the invention, production and marketing

of remdesivir and Captisol were trained at KU under Stella. "In 2001, I was fortunate to join a team of scientists and business

entrepreneurs, many of whom are KU graduates, to develop and commercialize the nascent Captisol technology," said James

Pipkin, vice president of new product development at Ligand, who earned his pharmaceutical chemistry degree from KU in

1981. "Captisol has a proud tradition with KU. The last few months have been intense as Ligand works closely with Gilead to

provide support for its use in formulating remdesivir. More Captisol than ever before may be required to make remdesivir

available for treating COVID-19 in the U.S. and around the world. I'm grateful for the education and mentoring I received at

KU and the opportunity to participate with innovators to create and make available on a global scale many life-saving and life-

changing medicines, but none more urgently important than remdesivir." Those contributing to the manufacture of the drug,

along with medical professionals and policymakers, are optimistic that remdesivir can make a difference to people being

treated for serious COVID-19 infection[48] "FDA's emergency authorization of remdesivir, two days after the National

Institutes of Health's clinical trial showed promising results, is a significant step forward in battling COVID-19," Alex Azar,

secretary of Health and Human Services said in a statement. For Stella, Captisol and his many other important contributions




to pharmaceutical chemistry can best be measured by the benefit they have to human health. "It's not publishing the papers,

it's not earning the grants, it's not the accolades you receive," Stella said. "It's the impact you make on people's lives. And that's

been my mantra to myself and to my kids. It's a very humbling experience, let me tell you, because you don't necessarily start

off thinking that way, even though people might say they did in retrospect. You know, I just wanted to be a professor, a teacher

and a researcher and I had some great mentors along the way. Then, as I've realized the work that I did was so impactful, it's

been pretty humbling."

Fig 1 Structure of captisol

Fig.2 DRUG + CAPTISOL = 1:1 DRUG CAPTISOL COMPLEX

In framing the complex, the physicochemical and organic properties of the medication can be adjusted to impact

an advantage.[49] The renal harmfulness of α-CD and β-CD after parenteral organization (Frank et al., 1976) just

as issues with various changed CDs have been all around recorded (Irie and Uekama, 1997; Thompson, 1997;

Gould and Scott, 2005). The wellbeing of certain CDs will be talked about later in this article.[50] Two altered

CDs have been distinguished as having great consideration complexation and maximal in vivo security for

different biomedical employments. They are SBE-β-CD, or Captisol, a polyanionic dynamically subbed

sulfobutyl ether of β-CD, and HP-β-CD, a changed CD industrially created by Janssen. SBE-β-CD and HP-β-CD

have experienced broad security examines and are as of now utilized in any event six Food and Drug

Administration (FDA)- affirmed items (four for SBE-β-CD and two for HP-β-CD).[51] Recently, there has been

enthusiasm for two extra subsidiaries, sugammadex or Org-25969 (Adam et al., 2002), in which the 6-hydroxy

gatherings (eight taking all things together) on γ-CD have been supplanted via carboxythio acetic acid derivation

ether linkages, and hydroxybutenyl-β-CD (Buchanan et al., 2002 , Buchanan et al., 2006).[52] There has

additionally been a reestablished enthusiasm for γ-CD itself and altered γ-CDs including HP-γ-CD.

IX. DRUG IS STRONGLY BOUND TO A CYCLODEXTRIN, HOW IS IT RELEASED?

This inquiry has been tended to in different articles and reviews.often sufficiently portray the cooperation of

medications with CDs. The balance steady can likewise be characterized as the proportion of the forward and

switch rate constants for this process.[53] For both feebly and firmly bound medications, we have endeavored to

quantify the energy of this procedure by different quick energy methods; for no situation have we had the option

to assess either the "on" or "off" rate—that is, the procedures are quicker than could be estimated. Others have

noted qualities for these energy utilizing ultra quick energy methods (Cramer et al., 1967; Rohrbach and Wojcik,

1981; Hersey and Robinson, 1984; Hersey et al., 1986) and have discovered that as a rule, rates approach those

of dispersion controlled limits.[54] In just one case (unpublished work) did we see some proof of moderate energy

when we watched atomic attractive reverberation (NMR) line expanding for a medication with a >1 × 105 M–1

restricting steady. In any case, on further examination, it was inferred that what we were taking a gander at was




entirely moderate interconversion between two distinctive bound types of the complex and not widening brought

about by delayed on/off rates.[55]

On the off chance that the on/off rates are quick, one can treat the response appeared in Scheme 1 as only a fast

harmony. Along these lines, the significant main thrust for medicate discharge from an incorporation complex is

straightforward weakening (Uekama et al., 1994; Rajewski and Stella, 1996; Stella and Rajewski, 1997; Stella et

al., 1999). Consider the parenteral infusion of a little volume to a human subject.[56] The volume of circulation

(Vd) for both SBE-β-CD and HP-β-CD is supposed to be that of extracellular water, about 20% of absolute body

weight or 14 L for a 70-kg quiet. A 5-mL infusion of a medication CD arrangement would bring about a 1:2,800

weakening. For most medications, this would be adequate to totally separate the medication from the CD.[57]

Only when the K esteem for the complex is >1 × 105 M–1 are any issues raised. Different systems can add to fast

medication discharge after organization (Stella et al., 1999).[58]

Notwithstanding weakening, they includedrug–protein restricting causing a decline in free medication fixation

and accordingly driving a left move of the harmony portrayed by Scheme 1, serious relocation by endogenous

and exogenous atoms, and medication take-up into tissues not available by the mind boggling or free CD.[59]

The job of serious dislodging raised some fascinating issues with the FDA after investigations with sugammadex

first surfaced. Sugammadex, an adjusted γ-CD, was intended to explicitly tie to rocuronium, a neuromuscular

blocker, and converse its bar. The coupling steady of rocuronium to sugammadex is supposed to be around 107

M–1 (Adam et al., 2002), an incentive far outside of the ordinary benefits of authoritative of about totally realized

medications to any CD, aside from another bizarre case—a progression of antimalarials (Perry et al., 2006;

Charman et al., 2006) official to SBE-β-CD.[60] As noted prior, when restricting constants are more prominent

than 1 × 105 M–1, it is more likely that collaborations may continue, even on weakening. Hence, an inquiry has

been raised: while a CD may be utilized to adequately convey a particular specialist, could that equivalent CD,

on foundational organization, tie to a second coadministered tranquilize and modify its pharmacodynamics and

pharmacokinetics? This has not been seen in any known cases, and one could sensibly contend this is a nonissue

aside from in the uncommon instance of a medication's having an unprecedented association with any of the

known approvable CDs. Indeed, even here, the impact ought to be short lived, on the grounds that the CDs are

quickly renally excreted.[61]

One may not need the complex to separate too totally now and again! For instance, Nagase et al. (2002) indicated

that SBE-β-CD diminished the hemolysis brought about by an exploratory medication when given IV contrasted

with the non-CD formulation.[62] Three of the business items utilizing SBE-β-CD endorsed by the FDA include

IM or SC organization of acidic arrangements of pitifully fundamental medications. IM or SC organization of

acidic arrangements of pitifully essential medications regularly brings about precipitation of the freebase type of

the medications, which thusly brings about flighty medication discharge from the infusion site. Such infusions

can likewise cause neighborhood tissue harm at the site of infusion as the pH quickly acclimates to 7.4. Cds, for

example, SBE-β-CD can keep the medication in arrangement and take into consideration complete and quick

delivery from the site of infusion, and on the grounds that the medication is fundamentally bound, they can

likewise bring down any neighborhood harmful response.[63] Once the medication CD mix is delivered to the

foundational course through weakening and different components examined over, the complex separates and

permits the medication to apply its activity.[64] The bringing down of nearby poisonous impacts has additionally

been seen for certain medications controlled ophthalmically (Järvinen et al., 1994; Järvinen, Järvinen, Urtii, et al.,

1995; Jarho et al., 1996; Loftsson and Järvinen, 1999).[65]

Consider the possibility that weakening is constrained. Oral organization of concentrated, high-volume CD–

tranquilize mixes to rodents frequently brings about diminished conveyance of medication atoms. The equivalent

is seen with some ophthalmic items (Järvinen et al., 1994 ; Järvinen, Järvinen, Urtti, et al., 1995; Jarho et al.,

1996). For instance, on account of ophthalmics, an eyedrop volume of 30 to 45 µL is weakened into just 7 to 10

µL of precorneal fluid.[66] Therefore, negligible weakening happens. In the event that the CD is utilized to impact

an answer of an ineffectively dissolvable medication, a particular bit of leeway despite everything happens

(Loftsson and Järvinen, 1999), however on the off chance that, for instance, abundance CD is utilized to balance

out the medication, at that point deficient free medication is accessible for corneal pervasion. A report by Rajewski

and Stella (1996) and various papers from the Loftsson's gathering have widely examined this issue.[67]




Compact discs have frequently been utilized to improve the dissolvability and oral conveyance of inadequately

water-solvent medications.[68] Two genuine models are an examination by Liversidge and Cundy (1995)

demonstrating the improved accessibility of an ineffectively water-dissolvable medication, danazol, and an

investigation by Järvinen, Järvinen, Schwarting, et al. (1995) demonstrating the expanded accessibility of

cinnarizine from different CD blends contrasted with some non-CD formulations[69] This has been particularly

fruitful when the medication CD mix has been utilized in bigger creature species, for example, canines and man.

Comparative outcomes have likewise been found in rodents when little volumes are directed. In any case, an issue

frequently emerges when one endeavors to heighten the portion of the medication for toxicology examines. In

heightening the portion of medication, one additionally raises the CD fixation, and the complete volume directed

can be as high as a few mL/kg.[70] This volume can rule the gastrointestinal lot ( GIT ) of the rat, and if a high

convergence of CD is utilized (regularly dependent upon 20% to 40%), being hypertonic can bring about free

stools and the runs (see later comments).[71] Thus, there is negligible weakening, bringing about low free-

tranquilize focus, and the shorter GIT travel time brings about a restraint of GIT retention of the drug.[72] This

has likewise been seen under comparative conditions when exceptionally high centralizations of surfactants are

used.[73] In outline, to make better conveyance and medication arrival of tricky medications from CDs.[74] one

must see how medications tie to CDs and perceive that CDs don't carry on in a similar way as medications added

to a cosolvent to impact a solution.[75]

X. CONCLUSION:

Conventional plan frameworks for insoluble as well as insecure dynamic pharmaceutical fixings (APIs) have

included a blend of natural solvents, surfactants and extraordinary pH conditions. These definitions may

accelerate upon infusion, or may cause disturbance and unfriendly responses. On occasion, these methodologies

are lacking for solubilizing enough dynamic specialist for a favored definition. Unbiased, cationic and anionic

APIs have been viably connected with Captisol®. Fluid solubilities have expanded by a factor of 10 to 25,000,

contingent upon the compound. Rather than other solubilization advancements, item or customary detailing

framework, the possibility and solvency viability of Captisol® can be quickly evaluated with a couple of basic

lab tests. Regularly, the inalienable pharmacokinetics and pharmacodynamics of the medication are unaffected

by Captisol®, anyway beginning might be controlled and portion saving possibly watched contrasted with old

style details, for example, co-dissolvable based, emulsions or suspensions. Upon organization, Captisol® is

promptly and basically totally renally dispensed with. Captisol® plans are biocompatible and can be directed

parenterally, orally, ophthalmically, nasally, topically and by means of inward breath. Captisol® was intended to

boost wellbeing by disposing of the possibly harming impacts delivered by the parent beta-cyclodextrin. In-vitro

tests and in-vivo intense, subchronic and incessant poisonousness considers have given security information to

help the turn of events and endorsement of Captisol® sedate definitions in man. Cooperation with Captisol®

gives a useful and secured condition for the API in its lipophilic cavity, while Captisol's hydrophilic surface gives

brilliant water solvency boosting both dissolvability and soundness. Association of the API with Captisol® can

decrease deterioration by shielding labile locales from the possible reactants in the watery condition. Utilizing

Captisol® from the get-go in the improvement procedure can build the quantity of competitors that can be

assessed, decline advancement time and increment lead applicant survivability. Captisol® empowers a watery

definition for some water insoluble APIs as oral, nasal, skin, ophthalmic or fluid introduced prescriptions.

XI. ACKNOWLEDGEMENTS

The authors are thankful to guide and Institute of SND College of Pharmacy, Babulgaon. For Providing the

neccessory facilities to prepare the manuscripts in the current format.

XII. REFERENCES:

1. Caltabiano AM. Quantitation of sulfobutyl ether-β-cyclodextrin (Captisol®) in Vestipitant IV solution by liquid

chromatography with ultraviolet (UV) detection. J Pharm Biomed Anal [Internet]. 2016;118:276–83.

2. Stella VJ, he Q. Cyclodextrins. Toxicol Pathol. 2008;36(1):30–42.

3. Tabuteau H. Pharmaceutical Compositions Comprising Meloxicam [Internet]. 2018. p. 1

4. Qiu Z. Orlistat inclusion compound and preparation method and application thereof in antineoplastic medicines [Internet].

2017. p. 1–11. Available from https://patents.google.com/patent/CN106943605A/en?oq=CN106943605A




5. Yina J. Ganciclovir eye preparation and preparation method thereof [Internet]. 2015. p. 1–5. Available from:

https://patents.google.com/patent/CN104606682A/en?oq=CN104606682A

6. Kfoury M, Pipkin JD, Antle V, Fourmentin S. Captisol®: an efficient carrier and solubilizing agent for essential oils and

their components. Flavour Fragr J. 2017;32(5):340–6.

7. Judit Horvath. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

[Internet]. 2018. p. 1–48. Available from:

https://patents.google.com/patent/US9895369B2/en?oq=US+9%2C895%2C369+B2

8. Crawley SE. Transdermal formulations of pergolide and uses thereof [Internet]. 2018. p. 1–16. Available from:

https://patents.google.com/patent/US9987267B2/en?oq=US+9%2C987%2C267+B2

9. Oh CK. Novel formulations of carvedilo [Internet]. 2003. p. 1–14. Available from:

https://patents.google.com/patent/WO2003028718A1/en?oq=WO03%2F028718A1

10. ROWE V-ND. Compositions useful for reducing nephrotoxicity and methods of use thereof [Internet]. 2007. p. 1–41.

Available from: https://patents.google.com/patent/WO2007062403A2/en?oq=WO2007%2F062403+A2

11. Jingchuan S. A method luteolin / SBE-β-CD inclusion complex prepared by. 2015. p. 1–14.

12. Antle VD. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same [Internet].

2017. p. 1–44. Available from: https://patents.google.com/patent/US20170275388A1/en?oq=US2017%2F0275388+A1

13. Pipkin J. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose

suspension [Internet]. 2007. p. 1–49. Available from:

https://patents.google.com/patent/US20070020196A1/en?oq=US2007%2F0020196+A1

14. Sabina K. Stabilized glycopeptide antibiotic formulations [Internet]. 2017. p. 1–81. Available from:

https://patents.google.com/patent/WO2017194385A1/en?oq=WO2017194385A1

15. Shang Jingchuan. Resveratrol-sulfobutyl ether-beta-cyclodextrin inclusion compound and preparing method thereof

[Internet]. 2016. p. 1–19. Available from: https://patents.google.com/patent/CN105903033A/en?oq=CN105903033A

16. Tong Keqin. Cabazitaxel composition for injection and preparation method there of[Internet]. 2018. p. 1–19. Available

from: https://patents.google.com/patent/CN108066774A/en?oq=CN108066774A

17. Reddy K. Neuroactive steroid formulations and methods of treating cns disorders [Internet]. 2013. p. 1–128. Available

from: https://patents.google.com/patent/WO2013112605A2/en?oq=WO2013%2F112605+A2

18. Diane O. Thompson GLM. Formulations containing propofol and a sulfoalkyl ether cyclodextrin [Internet]. 2006. p. 1–

27. Available from: https://patents.google.com/patent/US7034013B2/en?oq=US+7%2C034%2C013+B2

19. Mingjin Fan, Ujjwal Joshi, Jonathan Cam LJ. Method for Screening Lyophilized Parenteral Formulations [Internet].

2015. p. 1–32. Available from: https://patents.google.com/patent/US20150316568A1/en?oq=US2015%2F0316568+A1

20. I. ELETCGEMRC and I, Thelen D, Martin JA, Allen SM, SA S. Intravenous ganaxolone formulations and methods of

use in treating status epilepticus and other seizure disorders [Internet]. 2016. p. 1–22. Available from:

https://patents.google.com/patent/US20160228454A1/en?oq=US2016%2F0228454+A1

21. Strickley RG. Intravenous formulations of a late sodium current inhibitor [Internet]. 2017. p. 1–19. Available from:

https://patents.google.com/patent/WO2017007805A1/en?oq=WO+2017%2F007805+Al

22. Captisol® [Internet]. [cited 2018 Dec 5]. p. 1–1. Available from: https://www.Captisol.com/about

23. Marques HMC. A review on cyclodextrin encapsulation of essential oils and volatiles. Flavour Fragr J. 2010;25(5):313‐

326.

24. Kfoury M, Borgie M, Verdin A, et al. Essential oil components decrease pulmonary and hepatic cells inflammation induced

by air pollution particulate matter. Environ Chem Lett. 2016;14(3):345‐351.

25. Turek C, Stintzing FC. Stability of essential oils: A review. Comprehensive Reviews in Food Science and Food Safety.

Compr Rev Food Sci Food Saf. 2013;12(1):40‐53.

26. Crini G. Review: a history of cyclodextrins. Chem Rev. 2014;114(21):10940‐10975.

27. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev. 1998;98(5):1743‐1753.

28. Thompson DO. Cyclodextrin‐enabling excipients; their present and future use in pharmaceuticals. Crit Rev Ther Drug

Carrier Systems. 1997;14(1):1‐104.

29. Kfoury M, Landy D, Auezova L, Greige‐Gerges H, Fourmentin S. Effect of cyclodextrin complexation on

phenylpropanoids' solubility and antioxidant activity. Beilstein J Org Chem. 2014a;10:2322‐2331.

30. Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 2005;302(1‐2):18‐

28.

31. Salústio PJ, Pontes P, Conduto C, et al. Advanced Technologies for Oral Controlled Release: Cyclodextrins for Oral

Controlled Release. AAPS PharmSciTech. 2011;12(4):1276‐1292.




32. Yang Z, Xiao Z, Ji J. Solid inclusion complex of terpinen‐4‐ol/ β‐cyclodextrin: kinetic release, mechanism and its

antibacterial activity. Flavour Fragr J. 2015;30:179‐187.

33.Johnson MD et al. Solubilization of a tripeptide HIV protease inhibitorusing a combination of ionization and complexation

with chemically modified cyclodextrins. J Pharm Sci 1994; 83(8): 1142–1146.

34 Tokihiro K et al. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous

solution. Chem Pharm Bull 1997; 45(3): 525–531.

35. Zia V et al. Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7m-

Beta-CD to HP-Beta- CD. Pharm Res 2001; 18(5): 667–673.

36. Ueda H et al. Evaluation of a sulfobutyl ether beta-cyclodextrin as a solubilizing/stabilizing agent for several drugs. Drug

Dev Ind Pharm 1998; 24(9): 863–867.

37. Uekama K et al. Stabilizing and solubilizing effects of sulfobutyl ether bcyclodextrin on prostaglandin E1 analogue. Pharm

Res 2001; 18(11): 1578–1585.

38. Narisawa S, Stella VJ. Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation

with (SBE)(7m)- beta-CD. J Pharm Sci 1998; 87(8): 926–930.

39. Tokihiro K et al. Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether beta-cyclodextrin in rats. J

Pharm Pharmacol 2000; 52(8): 911–917.

40. Lefeuvre C et al. Biopharmaceutics and pharmacokinetics of 5-phenyl- 1,2-dithiole-3-thione complexed with sulfobutyl

ether-7-beta-cyclodextrin in rabbits. J Pharm Sci 1999; 88(10): 1016–1020.

41. Okimoto K et al. Design and evaluation of an osmotic pump tablet (opt) for prednisolone, a poorly water soluble drug,

using (SBE)(7m)-beta- CD. Pharm Res 1998; 15(10): 1562–1568.

42. Kaukonen AM et al.Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation

of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. J Pharm Pharmacol 1998; 50(6): 611–

619.

43. Jarho P et al. The use of cyclodextrins in ophthalmic formulations of dipivefrin. Int J Pharm 1997; 153: 225–233.

44. Jarho P et al. Modified beta-cyclodextrin (SBE7-b-CyD) with viscous vehicle improves the ocular delivery and tolerability

of pilocarpine prodrug in rabbits. J Pharm Pharmacol 1996; 48: 263–269.

45. Adam, J. M., Bennett, D. J., Born, A., Clark, J. K., Feilden, H., Hutchinson, E. J., Palin, R., Prosser, A., Rees, D. C.,

Rosair, G. M., Stevenson, D., Tarver, G. J., and Zhang, M-Q. (2002). Cyclodextrin-derived host molecules as reversal agents

for the neuromuscular blocker recuronium bromide: synthesis and structure-activity relationships. J Med Chem 45, 1806-16.

46.Albers, E., and Muller, B. W. (1995). Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst 12, 311-

37.

47.Antlsperger, G., and Schmid, G. (1996). Toxicological comparison of cyclodextrins. In Proceedings of 8th International

Symposium on Cyclodextrins (J. Szejtli and L. Szente, eds., pp. 149-55). Kluwer Academic Publishers, Dordrecht, the

Netherlands.

48.Baldrick, P., and Bamford, D. G. (1997). A toxicological review of lactose to support clinical administration by inhalation.

Food Chem Toxicol 35, 719-33.

49.Barrow, P. C., Olivier, P., and Marzin, D. (1995). The reproductive and developmental toxicity profile of β-cyclodextrin

in rodents. Reprod Toxicol 9, 389-98.

50.Bellringer, M. E., Smith, T. G., Read, R., Gopinath, C., and Olivier, P. (1995). β-Cyclodextrin: 52-week toxicity studies in

the rat and dog. Food Chem Toxicol 33, 367-76.

51.Lambert, J. L., Lowman, D. W., Offerman, R. J., Szejtli, J., and Szente, L. (2002). Synthesis and characterization of water-

soluble hydroxybutenyl cyclomaltooligosaccharides (cyclodextrins). Carbohydr Res 337, 493-507.

52.Buchanan, C. M., Buchanan, N. L., Edgar, K. J., Lambert, J. L., Posey-Dowty, J. D., Ramsey, M. G., and Wempe, M. F.

(2006). Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes. J Pharm Sci 95, 2246-55.

53.Carpenter, T. O., Gerloczy, A., and Pitha, J. (1995). Safety of parenteral hydroxypropyl β-cyclodextrin. J Pharm Sci 84,

222-5.

54.Challa, R., Ahuja, A., Ali, J., and Khar, R. K. (2005). Cyclodextrins in drug delivery: An updated review. AAPS Pharmsci

Tech 6, E329-57.

55.Charman, S. A., Perry, C. S., Chiu, F. C., McIntosh, K. A., Prankerd, R. J., and Charman,W. N. (2006). Alteration of the

intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci 95,

256-67.

56.Cramer, F., Saenger,W., and Spatz, H.-Ch. (1967). Inclusion compounds. XIX. The formation of inclusion compounds of

α-cyclodextrin in aqueous solutions. Thermodynamics and kinetics. J Amer Chem Soc 89, 14-20.

57.Davies, B. and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10, 1093-5.




58.De Bie, A. T.,Van Ommen, B., and Bar, A. (1998). Disposition of γ-cyclodextrin in germ-free and conventional rats. Regul

Toxicol Pharmacol 27, 150-8.

59.Dietzel, K., Estes, K. S., Brewster,M. E., Bodor, N. S., and Derendorf, H. (1990). The use of 2-hydroxypropyl-β-

cyclodestrin as a vehicle for intravenous administration of dexamethasone in dogs. Int J Pharm 59, 225-30.

60.Donaubauer, H. H., Fuchs, H., Langer, K. H., and Bar, A. (1998). Subchronic intravenous toxicity studies with γ-

cyclodextrin in rats. Regul Toxicol Pharmacol 27, 189-98.

61.Duchéne, D. (1987). Cyclodextrins and Their Industrial Uses. Editions de Santé, Paris. Frank, D. W., Gray, J. E., and

Weaver, R. N. (1976). Cyclodextrin nephrosis in the rat. Am J Pathol 83, 367-82.

62.Frijlink, H. W., Eissens, A. C., Hefting, N. R., Poelstra, K., Lerk, C. F., and Meijer, D. K. (1991). The effect of parenterally

administered cyclodextrins oncholesterol levels in the rat. Pharm Res 8, 9-16.

63.Frijlink, H. W.,Visser, J., Hefting, N. R., Oosting, R., Meijer, D. K., and Lerk, C. F. (1990). The pharmacokinetics of β-

cyclodextrin and hydroxypropyl-β- cyclodextrin in the rat. Pharm Res 7, 1248-52.

64.Frömming, K., and Szejtli, J. (1994). Cyclodextrins in Pharmacy. Kluwer Academic Publishers, Dordrecht, the

Netherlands. Gerloczy, A., Antal, S., Szathmari, I., Muller-Horvath, R., and Szejtli, J. (1990). pp. 507-13)

65.He, Y., and Yalkowsky, S. H. (2006). Solubilization of monovalent weak electrolytes by micellization or complexation.

Int J Pharm 314, 15-20.

66.Henics, T., and Wheatley, D. N. (1999). Cytoplasmic vacuolation, adaptation and cell death: a view on new perspectives

and features. Biol Cell 91, 485-98.

67.Hersey, A., and Robinson, B. H. (1984). Thermodynamic and kinetic study of the binding of azo-dyes to α-cyclodextrin. J

Chem Soc Faraday Trans 1 80, 2039-52.

68.Hersey, A., Robinson, B. H., and Kelly, H. C. (1986). Mechanism of inclusioncompound formation for binding of organic

dyes, ions and surfactants to α-cyclodextrin studied by kinetic methods based on competition experiments. J Chem Soc Faraday

Trans 1 82, 1271-87.

69.Irie, T., and Uekama, K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety

evaluation. J Pharm Sci 86, 147-62.

70.Jarho, P., Järvinen, K., Urtti, A., Stella, V. J., and Järvinen, T. (1996). Modified

β-cyclodextrin (SBE7-β-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in

rabbits. J Pharm Pharmacol 48, 263-9.

71.Jarho, P., Vander Velde, D., and Stella, V. J. (2000). Cyclodextrin-catalyzed deacetylation of spironolactone is pH and

cyclodextrin dependent. J Pharm Sci 89, 241-9.

72.Järvinen, T., Järvinen, K., Schwarting, N., and Stella,V. J. (1995). β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD,

increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci 84, 295-9.

73.Järvinen, K., Järvinen, T., Thompson, D., and Stella, V. J. (1994). The effect of modified β-cyclodextrins, SBE4-β-CD, on

the aqueous stability and ocular absorption of pilocarpine. Curr Eye Res 13, 897-905.

74.Järvinen, T., Järvinen, K., Urtti, A., Thompson, D., and Stella, V. J. (1995). Sulfobutyl ether β-cyclodextrin (SBE-β-CD)

in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J Ocul Pharmacol Ther 11, 95–106.

75.Koutsou, G. A., Storey, D. M., and Bar, A. (1999). Gastrointestinal tolerance of γ-cyclodextrin in humans. Food Addit

Contam 16, 313-7.


a brief review on captisol

Documents